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Purpose: To analyze mitochondrial DNA (mt DNA) gene mutations in a 19-year-old female patient, who presented with
chronic progressive external ophthalmoplegia (CPEO), together with her mother and younger sister.
Methods: The diagnosis of mitochondrial myopathy was made based on clinical and biologic analysis. Histochemical
methods were used to detect ragged-red fibers (RRFs) and ragged-blue fibers (RBFs) on a muscle biopsy of the patient.
All mitochondrial gene DNA fragments of the patient, her mother, and younger sister were amplified by polymerase chain
reaction. The products were sequenced and compared with reference databases.
Results: A novel T1658C mutation and a known A10006G mutation were identified in the mitochondrial tRNAVal gene
and the tRNAGly gene, respectively, in the patient, her mother, and younger sister. The T1658C mutation changes the T
loop structure of mitochondrial tRNAVal and the A10006G mutation disturbs the D loop of mitochondrial tRNAGly.
Conclusions: The T1658C and A10006G mutations of mtDNA may be responsible for the pathogenesis of the patient
with CPEO.
Mitochondrial myopathies, usually maternally inherited
and involving multiple organs, are a group of neuromuscular
diseases  caused  by  mitochondrial  dysfunction  [1].  Most
mitochondrial myopathies occur before the age of 20 and often
begin  with  exercise  intolerance  or  muscle  weakness.
Prognoses for the disorders are poor, with severity ranging
from progressive weakness to death [2].
Chronic progressive external ophthalmoplegia (CPEO) is
the most common mitochondrial myopathy, making up an
estimated  two-thirds  of  all  incidences  of  mitochondrial-
associated  disorders.  Patients  typically  present  with
progressive  paralysis  of  the  extraocular  muscles.  Patients
usually  experience  bilateral,  symmetric,  and  progressive
ptosis, followed by ophthalmoparesis months or years later.
Deletions and mutations of mitochondrial DNA lead to CPEO,
and  several  point  mutations  in  mitochondrial  tRNA  (mt
tRNA) genes are known to be associated with CPEO [3].
METHODS
Patient  and  controls:  A  19-year-old  female  Han  Chinese
patient presented with progressive bilateral blepharoptosis,
which was first noticed at age 13. The symptoms were neither
alleviated in the morning nor aggravated in the evening. She
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was prone to fatigue after exercise. The family medical history
was not significant. A complete clinical examination of both
her mother and sister had been performed and no disorders
were noticed. This patient and her family were recruited from
the clinic at the Department of Ophthalmology, West China
Hospital, Sichuan University, Chengdu, People’s Republic of
China. One hundred and forty-eight control subjects, random
normal Han Chinese living in the same region as the patient,
were also recruited from the West China Hospital. The study
was approved by the West China Hospital Sichuan University
Institute Review Board. This study adhered to the tenets of the
Declaration of Helsinki.
Histological  examination:  An  open  muscle  biopsy  was
performed by obtaining tissue through a small incision from
the patient’s left musculus biceps brachii. The biopsy was
divided into two parts: one part was snap frozen in isopentane
pre-cooled in liquid nitrogen for cryosections, and the other
part was fixed in 10% buffered formalin for routine paraffin
embedded  sections.  The  sections  were  stained  with
hematoxylin-eosin  (H&E),  modified  Gomori  trichrome
(MGT), and succinate dehydrogenase (SDH).
Mutation analysis of the mitochondrial genome: Genomic
DNA  was  isolated  from  whole  blood  of  the  patient,  her
mother, and sister using the phenol-chloroform method. First,
the three individuals’ DNA fragments spanning the whole
mitochondrial gene were amplified by PCR using 24 pairs of
oliodeoxynucleotides (Table 1) which sets the light (L) strand
and the heavy (H) strand [4]. The overlapping PCR products
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1736TABLE 1. PRIMERS USED IN POLYMERASE CHAIN REACTION FOR AMPLIFICATION OF THE ENTIRE MITOCHONDRIAL GENOME .
Primer Sequence (5’→3’) Annealing
temperature (°C)
Size of
product
1 Forward: CTCCTCAAAGCAATACACTG 56 839
  Reverse: TGCTAAATCCACCTTCGACC    
2 Forward: CGATCAACCTCACCACCTCT 57 801
  Reverse: TGGACAACCAGCTATCACCA    
3 Forward: GGACTAACCCCTATACCTTCTGC 58 859
  Reverse: GGCAGGTCAATTTCACTGGT    
4 Forward: AAATCTTACCCCGCCTGTTT 57 886
  Reverse: AGGAATGCCATTGCGATTAG    
5 Forward: TACTTCACAAAGCGCCTTCC 57 831
  Reverse: ATGAAGAATAGGGCGAAGGG    
6 Forward: TGGCTCCTTTAACCTCTCCA 56 903
  Reverse: AAGGATTATGGATGCGGTTG    
7 Forward: ACTAATTAATCCCCTGGCCC 57 978
  Reverse: AATGGGGTGGGTTTTGTATG    
8 Forward: CTAACCGGCTTTTTGCCC 56 813
  Reverse: ACCTAGAAGGTTGCCTGGCT    
9 Forward: GAGGCCTAACCCCTGTCTTT 59 827
  Reverse: ATTCCGAAGCCTGGTAGGAT    
10 Forward: CTCTTCGTCTGATCCGTCCT 58 885
  Reverse: AGCGAAGGCTTCTCAAATCA    
11 Forward: ACGCCAAAATCCATTTCACT 55 986
  Reverse: CGGGAATTGCATCTGTTTTT    
12 Forward: ACGAGTACACCGACTACGGC 58 909
  Reverse: TGGGTGGTTGGTGTAAATGA    
13 Forward: TTTCCCCCTCTATTGATCCC 57 815
  Reverse: GTGGCCTTGGTATGTGCTTT    
14 Forward: CCCACCAATCACATGCCTAT 57 939
  Reverse: TGTAGCCGTTGAGTTGTGGT    
15 Forward: TCTCCATCTATTGATGAGGGTCT 58 892
  Reverse: AATTAGGCTGTGGGTGGTTG    
16 Forward: GCCATACTAGTCTTTGCCGC 60 859
  Reverse: TTGAGAATGAGTGTGAGGCG    
17 Forward: TCACTCTCACTGCCCAAGAA 56 801
  Reverse: GGAGAATGGGGGATAGGTGT    
18 Forward: TATCACTCTCCTACTTACAG 55 865
  Reverse: AGAAGGATATAATTCCTACG    
19 Forward: AAACAACCCAGCTCTCCCTAA 56 976
  Reverse: CGATGATGTGGTCTTTGGA    
20 Forward: ACATCTGTACCCACGCCTTC 58 969
  Reverse: AGAGGGGTCAGGGTTGATTC    
21 Forward: GCATAATTAAACTTTACTTC 55 937
  Reverse: AGAATATTGAGGCGCCATTG    
22 Forward: TGAAACTTCGGCTCACTCCT 57 1161
  Reverse: AGCTTTGGGTGCTAATGGTG    
23 Forward: TCATTGGACAAGTAGCATCC 55 809
  Reverse: GAGTGGTTAATAGGGTGATAG    
24 Forward: CACCATCCTCCGTGAAATCA 55 963
  Reverse: AGGCTAAGCGTTTTGAGCTG    
         Summary of the primer sequences, annealing temperatures, and size of products used for the amplification of the entire
         mitochondrial genome.
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1737were purified and subsequently analyzed by direct sequencing
in an ABI 3700 automated DNA sequencer using the Big Dye
Terminator  Cycle  sequencing  reaction  kit.  Next,  two
mitochondrial regions covering 1658 and 10006 from 148
control DNA samples were amplified by PCR and sequenced.
RESULTS
The  patient—the  only  subject  manifesting  CPEO  in  the
pedigree—had  previously  undergone  thorough  ophthalmic
examinations. Her visual acuity was 20/80 in the right eye
(O.D.)  and  20/100  in  the  left  eye  (O.S.).  Bilateral  and
asymmetric ptosis was noticed. The palpebral aperture was
3 mm for the O.D. and 5 mm for the O.S. The abduction and
adduction  of  the  left  eye  were  mildly  limited,  yet  the
supraduction  and  deorsumduction  appeared  normal.  The
movement of the left eye was normal. Binocular diplopia was
noticed in all directions. Both pupils were equal, round, and
reactive to light. The anterior segment was unremarkable.
Visual evoked potential showed P100 latency (positive peak
at  around  100  ms)  was  delayed  in  both  eyes  and  P100
amplitude was reduced in the O.D.
Other examinations included neurologic examinations,
laboratory tests, and a skeletal muscle biopsy. The muscle
strength of proximal extremities was normal (5/5), but was
slightly weak at the distal end (4/5). The muscular tension of
extremities  was  within  normal  limits  and  myotonia  was
absent. Deep reflexes and sensation were normal. Routine
blood  and  urine  tests  were  unremarkable.  A  magnetic
resonance  imaging  (MRI)  scan  of  the  head  showed  no
abnormality. The antinuclear antibody (ANA) was negative.
An electromyologram (EMG) showed the right ulnar nerve
has no abnormality in low and high frequency stimulation.
Histological examinations showed ragged-red fibers (RRFs)
and ragged-blue fibers (RBFs) on the patient’s muscle biopsy
(Figure  1),  consistent  with  the  pathological  features  of
mitochondrial myopathy.
To determine the role of mitochondrial abnormalities in
the  pathogenesis  of  this  patient  with  CPEO,  the  24  PCR
fragments spanning the entire mitochondrial genome of the
affected  individual,  her  mother,  and  younger  sister  were
analyzed  by  direct  sequencing.  The  comparison  of  the
resultant sequences with the Revised Cambridge Reference
Sequence [5] revealed several nucleotide changes, as shown
in Table 2, Figure 2, and Figure 3. The patient’s mitochondrial
sequence results are identical to those of her mother and sister,
except the T1658C mutation of the patient’s young sister is T/
C heterozygous in the mitochondrial tRNAVal gene. There
were no T1658C or A10006G mutations in the148 control
subjects.
DISCUSSION
Chronic progressive external ophthalmoplegia, characterized
by limited ocular motility in all directions of gaze and ptosis,
is the most common manifestation of mitochondrial myopathy
and usually occurs in young adulthood. Ptosis is usually the
first  clinical  sign,  but  ophthalmoplegia  may  not  become
apparent  for  months  or  even  years.  The  ptosis  is  usually
bilateral and symmetric.
The diagnosis of CPEO relies upon a combination of
different  approaches,  including  clinical  data,  neurologic
examinations, laboratory tests, and a skeletal muscle biopsy.
Ragged-red fibers on muscle biopsies are observed in a wide
variety of mitochondrial diseases. The presence of more than
2% RRFs on skeletal muscle biopsies can be considered one
of the criteria required for the diagnosis of mitochondrial
disease. Figure 1 shows RRFs and RBFs on the patient’s
muscle biopsy. Stained with MGT staining, one can see an
accumulation  of  enlarged  mitochondria  in  the  RRFs.
Therefore, changes and dysfunction of mitochondria are the
pathogenesis of CPEO.
Over the past two decades, numerous genetic causes of
CPEO have been described [6-30]. Most present at mt tRNA
genes,  affecting  mitochondrial  tRNALeu(UUR),  tRNAIle,
tRNAAla, tRNAAsn, tRNALys, tRNALeu(CUN), and tRNAGly genes,
including  A3243G,  T3250C,  and  C3254T  in  the
tRNALeu(UUR) gene; T4274C, T4285C, G4298A, and G4309A
in the tRNAIle gene; T5628C in the tRNAAla gene; T5692C and
G5703A  in  the  tRNAAsn  gene;  G12294A,  A12308G,
T12311C,  and  12315A  in  the  tRNALeu(CUN)  gene;  and  an
A10006G mutation in the tRNAGly genes [6-30]. Most of these
Figure 1. Histological examination of left biceps from the patient. A: H&E staining shows an RRF (arrow). B: MGT staining shows an atypical
RRF (arrow). C: SDH staining shows ragged-blue fibers (arrows). Magnification 400×.
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1738point mutations in mt tRNA genes have been proved only once
and appeared to be limited to one patient or one family; some
point mutations have been reported in different pedigrees
[22]. Therefore, mt tRNA mutations play a pivotal role in the
pathogenesis of CPEO.
There are 44 nucleotide changes in this CPEO subject’s
mitochondrial genome that belong to haplogroup D4f. Most
nucleotide changes are polymorphisms and are not associated
with human diseases. However, two mutations in this subject,
T1658C in the tRNAVal gene and A10006G in the tRNAGly
gene, may be responsible for this disorder.
In fact, Lauber et al. [22] first reported a CPEO patient
with a tRNAGly A10006G mutation. Sternberg et al. [16] also
found this mutation in a patient with oculomotor myopathy.
TABLE 2. MTDNA NUCLEOTIDE CHANGES IN THE AFFECTED SUBJECT.
Gene Position Nucleotide change Amino acid change Previously reported*
D-loop 73 A→G   +
  263 A→G   +
  310 T→CTC   +
  489 T→C   +
  514 C→DEL   +
  515 A→DEL   +
  568 C→CCCC   +
  16223 C→T   +
  16362 T→C   +
  16519 T→C   +
12SrNA 750 A→G   +
  1382 A→C   +
  1438 A→G   +
TV 1658 T→C   -
16SrNA 2706 A→G   +
  3010 G→A   +
ND1 4769 A→G   +
ND2 4883 C→T   +
  5178 C→A L→M +
CO1 7028 C→T   +
CO2 8020 G→A   +
ATP8 8414 C→T L→F +
ATP6 8701 A→G T→A +
  8860 A→G   +
  8964 C→T   +
CO3 9296 C→T   +
  9540 T→C   +
  9545 A→G   +
  9824 T→A   +
TG 10006 A→G   +
ND3 10398 A→G T→A +
  10400 C→T   +
ND4 10790 T→C SYN -
  10873 T→C   +
  11014 C→T SYN -
  11719 G→A   +
ND5 12705 C→T   +
  13866 A→G SYN -
ND6 14668 C→T   +
CYB 14766 C→T T→I +
  14783 T→C   +
  15043 G→A   +
  15301 G→A   +
  15326 A→G T→A +
*See http://www.mitomap.org. The boldfaced are pathogenic mutations.
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1739Münscher et al. [14] identified tRNAGly A10006G, a mutation
known to be associated with aging, in patients with chronic
intestinal pseudo-obstruction (CIPO) and CPEO. Our results,
as exhibited in Figure 2D,E and Figure 3B, show the A10006G
mutation is located at position 16 on the D loop of tRNAGly.
Most importantly, this mutation changes the structure of the
D loop of mt tRNAGly. T1658C is a novel mutation, located at
position 57 of tRNAVal. Figure 2A-C show that wild type T at
position 57 matches with A at position 50 in tRNAVal. When
position 57 T changes to C, the mutant 57 C does not match
with position 50 A. Therefore, one base pair on the T arm of
tRNAVal is split and the T loop is extended.
Mitochondrion has its own tRNAs to carry amino acids
to  synthesize  mitochondrial  proteins  essential  for  ATP
production. Each tRNA is charged with the proper amino acid
via  a  covalent  ester  bond  at  their  3′  end  by  the  specific
aminoacyl-tRNA  synthetase.  In  our  study,  the  structural
changes  of  mt  tRNAGly  and  tRNAVal,  like  the  A3243G
mutation  in  mt  tRNALeu(UUR)  [30,31],  may  influence  their
structural  stability,  modifications,  3′  end  processing,  and
aminoacylations and decrease mitochondrial protein synthesis
and ATP production. Valine is one of these essential amino
acids. The defective mt tRNAVal will reduce the transportation
efficiency  for  valine,  leading  to  insufficient  valine  in  the
mitochondrial translation. Therefore, the T1658C mutation
leads to the T loop structural change of mt tRNAVal, indicating
a  role  in  the  development  of  CPEO  in  this  individual.
Furthermore,  the  mitochondrial  sequence  of  the  patient’s
younger sister is 1658 T/C heterozygous; however, her sister
has not manifested CPEO.
Muscle, especially extraocular muscle, consumes a lot of
energy.  Mitochondrial  tRNA  mutations  may  cause  the
Figure 2. mt tRNA sequence results from the affected subject (Mutant) and the control (Wild type). A, B, and C: T1658C mutation (A: Wild
type, B: Mutant, C: T/C Heteroplasmy). D and E: A10006G mutation (D: Wild type, E: Mutant). Arrows indicate the nucleotide changes.
Figure 3. Mutation positions located at
mt tRNAs in this patient. A: tRNAVal,
B:  tRNAGly.  *show  the  mutations  in
tRNAVal  (position  57)  and  tRNAGly
(position 16).
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1740dysfunction of mitochondrial translation. Our results suggest
that T1658C, a newly identified mutation as an independent
factor  or  one  associated  with the  A10006G  mutation,
may contribute to the pathogenesis of CPEO. However, the
molecular mechanisms of T1658C that cause CPEO and the
confounding effects of T1658C and A10006G mutations have
yet to be elucidated. To determine the role of the mutations
(T1658C and /or A10006G) in mitochondrial dysfunction, the
lymphoblastoid cell lines should be generated—using blood
from the patient and her family members, as well as control
subjects—and studied. Further study of the pathogenetic role
of  mtT1658C  in  CPEO  patients  with  this  mitochondrial
mutation only is also needed.
It   is   noted   that   the  DNA  extracted  from muscle
tissue should be more appropriate for use in the mutational
study than that extracted from blood since the changes in
muscular mtDNA would be more convincing in explaining
the involvement of selective extraocular muscles in CPEO.
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